Trulieve Cannabis Past Earnings Performance

Past criteria checks 0/6

Trulieve Cannabis's earnings have been declining at an average annual rate of -73.1%, while the Pharmaceuticals industry saw earnings growing at 26.2% annually. Revenues have been growing at an average rate of 37.4% per year.

Key information

-73.1%

Earnings growth rate

-68.6%

EPS growth rate

Pharmaceuticals Industry Growth23.1%
Revenue growth rate37.4%
Return on equity-30.9%
Net Margin-38.1%
Last Earnings Update31 Dec 2023

Recent past performance updates

Recent updates

Is Trulieve Cannabis (CSE:TRUL) A Risky Investment?

Feb 15
Is Trulieve Cannabis (CSE:TRUL) A Risky Investment?

There's Reason For Concern Over Trulieve Cannabis Corp.'s (CSE:TRUL) Massive 29% Price Jump

Jan 16
There's Reason For Concern Over Trulieve Cannabis Corp.'s (CSE:TRUL) Massive 29% Price Jump

Calculating The Intrinsic Value Of Trulieve Cannabis Corp. (CSE:TRUL)

Mar 06
Calculating The Intrinsic Value Of Trulieve Cannabis Corp. (CSE:TRUL)

These 4 Measures Indicate That Trulieve Cannabis (CSE:TRUL) Is Using Debt Extensively

Jan 26
These 4 Measures Indicate That Trulieve Cannabis (CSE:TRUL) Is Using Debt Extensively

Does Trulieve Cannabis (CSE:TRUL) Have A Healthy Balance Sheet?

Aug 07
Does Trulieve Cannabis (CSE:TRUL) Have A Healthy Balance Sheet?

Are Trulieve Cannabis Corp. (CSE:TRUL) Investors Paying Above The Intrinsic Value?

Jul 03
Are Trulieve Cannabis Corp. (CSE:TRUL) Investors Paying Above The Intrinsic Value?

These 4 Measures Indicate That Trulieve Cannabis (CSE:TRUL) Is Using Debt Reasonably Well

Mar 21
These 4 Measures Indicate That Trulieve Cannabis (CSE:TRUL) Is Using Debt Reasonably Well

Is Trulieve Cannabis (CSE:TRUL) Using Too Much Debt?

Aug 16
Is Trulieve Cannabis (CSE:TRUL) Using Too Much Debt?

With EPS Growth And More, Trulieve Cannabis (CSE:TRUL) Is Interesting

Jun 08
With EPS Growth And More, Trulieve Cannabis (CSE:TRUL) Is Interesting

Is Trulieve Cannabis (CSE:TRUL) Using Too Much Debt?

Apr 07
Is Trulieve Cannabis (CSE:TRUL) Using Too Much Debt?

Did Trulieve Cannabis Corp. (CSE:TRUL) Insiders Sell Shares?

Mar 03
Did Trulieve Cannabis Corp. (CSE:TRUL) Insiders Sell Shares?

Is Trulieve Cannabis Corp. (CSE:TRUL) Trading At A 48% Discount?

Feb 16
Is Trulieve Cannabis Corp. (CSE:TRUL) Trading At A 48% Discount?

Revenue & Expenses Breakdown
Beta

How Trulieve Cannabis makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

CNSX:TRUL Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 231,129-4313860
30 Sep 231,162-4774140
30 Jun 231,182-5274270
31 Mar 231,214-2054320
31 Dec 221,218-1794220
30 Sep 221,225-1854080
30 Jun 221,153-953760
31 Mar 221,055-373390
31 Dec 21932312960
30 Sep 21801932290
30 Jun 21714912020
31 Mar 21619691790
31 Dec 20522631510
30 Sep 20433-191320
30 Jun 20367231110
31 Mar 2030462910
31 Dec 1925353730
30 Sep 19209128700
30 Jun 1916785600
31 Mar 1913236510
31 Dec 1810311440
30 Sep 188033230
30 Jun 185516170
31 Mar 18339120
31 Dec 1720480
31 Dec 160-410

Quality Earnings: TRUL is currently unprofitable.

Growing Profit Margin: TRUL is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: TRUL is unprofitable, and losses have increased over the past 5 years at a rate of 73.1% per year.

Accelerating Growth: Unable to compare TRUL's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: TRUL is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (100.1%).


Return on Equity

High ROE: TRUL has a negative Return on Equity (-30.95%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.